Angiopoietin
(ANG) receptor plays a crucial role in regulation of vascular
permeability and pathological vascular remodelling during tumour angiogenesis,
metastasis and inflammation. Thus, it has emerged as a new clinical approach
for the development of therapeutics which treat cancer and ophthalmological
diseases.
The exclusive function of these receptors in vascular
stabilization also makes it an attractive target in organ transplantation,
sepsis, vascular complications of diabetes and atherosclerosis. There are
various types of angiopoietins identified which includes ANG-1, ANG-2, ANG-3
and ANG-4. ANG-2 is the most commonly targeted receptor for the treatment of
various diseases and demonstrated as potential therapeutics for
anti-angiogenesis treatment for patients suffering from cancer.
Request to Get the Sample Pages at:
Company like Regeneron Pharmaceuticals Inc. is developing a
combination of nesvacumab and aflibercept which acts as ANG-2 inhibitor and
vascular endothelial growth factor A inhibitor, respectively for the treatment
of retinal diseases (wet age-related macular degeneration and diabetic macular
oedema). F. Hoffmann-La Roche Ltd., Eli Lilly and Company, and Boehringer
Ingelheim International GmbH are some other key players having extensive
pipeline of angiopoietin inhibitors.
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with detailed analysis of pipeline and clinical trials. Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licencing, grants, technology and others.
